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92Early Central Nervous Complications after Umbilical
Cord Blood Transplantation for Adults
Hiroto Narimatsu,1,2 Koichi Miyamura,3 Hiroatsu Iida,4 Motohiro Hamaguchi,5
Toshiki Uchida,6 Yoshihisa Morishita7 for the Nagoya Blood and Marrow Transplantation
Group (NBMTG)Early central nervous complications (CNS) are significant after allogeneic stem cell transplantation; however,
the clinical characteristics of early CNS complications have not yet been well described. The medical record
of 77 patients who underwent cord blood transplantation (CBT) between March 2001 and November 2005,
at 8 centers of the Nagoya Blood and Marrow Transplantation Group were retrospectively reviewed. The
preparative regimen included myeloablative CBT (n 5 31) or reduced-intensity (RI)-CBT (n 5 46). Of
the 77 patients, 10 (13%) developed early CNS complications. Causes included Cyclosporine encephalopathy
(n 5 5), tacrolimus encephalopathy (n 5 2), thrombocytic microangiopathy (n 5 1), and unknown (n 5 3).
The median time of onset was 19 days (range: 2-58 days). All of the 10 patients developed impaired con-
sciousness. Seizures developed in 6 patients. Early CNS complications spontaneously subsided in 3 patients.
Three patients responded to cyclosporine or tacrolimus discontinuation. The remaining 4 patients died
within 30 days of developing of early CNS complications. No relationship was detected between the prepar-
ative regimen and the onset of early CNS complications, while an HLA disparity showed borderline signifi-
cance (hazard ratio, 3.24; 95% confidential interval, 0.94-11.20; P 5 .06). Early CNS complications are
a significant problem after CBT, and the clinician has to be aware of the possibility of these complications.
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Early central nervous system (CNS) complications
are a significant problem after allogeneic stem
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6/j.bbmt.2008.11.005regimen-related toxicities, infections, cerebrovascular
events, and metabolic disorders [2-8]. However,
information on these complications is limited due to
the difficulty in their diagnosis. Antemortem patho-
logic diagnosis based on a biopsy is highly difficult
during the thrombocytopenic period. Therefore, phy-
sicians usually manage this complication according to
the clinical diagnosis based on imaging studies, neuro-
logic findings, and cerebrospinal fluid examinations.
Cord blood transplantation (CBT) is an attractive
alternative for patients with advanced hematologicma-
lignancy who lack matched related or unrelated
donors. Adult patients receiving myeloablative or
reduced-intensity CBT (RI-CBT) have a 90% chance
of engraftment, but also experience a high rate of
transplant-related mortality [9-16]. A recent study on
RI stem cell transplantation indicated that patients
who received CBT were at higher risk of early CNS
complications than those who received peripheral
blood stem cell transplantation. However, the clinical
characteristics after CBT remain to be investigated,
whereas other complications, such as infection or
graft-versus-disease, have been addressed in recent
studies [15,17-19]. The present study investigated
the clinical characteristics of early CNS complications
after CBT.
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Study Patients
Between March 2001 and November 2005, a total
of 77 patients underwent CBT at 8 centers of the
Nagoya Blood and Marrow Transplantation Group
(NBMTG). The medical records of those patients
were retrospectively reviewed. All patients presented
with hematologic disorders that were incurable using
conventional treatments and were considered not
eligible for conventional allo-SCT due to the lack of
HLA-identical siblings or suitable unrelated donors.
Patients.50-years-old and/or with organ dysfunction
received RI-CBT. All patients provided their informed
consent prior to CBT.
Transplantation Procedures and Outcomes
The cord blood units were provided by the Japan
Cord Blood Bank Network, and they were processed
in each of their domestic cord blood banks that are
affiliated with the network. Cord blood units were
not depleted of T-lymphocytes. Purine analog-based
regimens were defined as RI preparative regimens.
Acute grave-versus-host disease (aGVHD) were
graded according to the established criteria [20].
GVHD prophylaxis involved continuous infusion of
cyclosporine 3 mg/kg or tacrolimus 0.03 mg/kg from
day 21 until the patient tolerated oral administration
with or without short-term MTX (Table 1). The
choice of the preparative regimen and a GVHD
prophylaxis was made based on the decision of the
physician or the specific institution.
Immune reactions were defined as previously de-
scribed [19]. When febrile patients (body temperature
$38C) with no evidence of infection or adverse ef-
fects of medication exhibited skin eruption, diarrhea,
jaundice (serum total bilirubin .2.0 mg/dL) or body
weight gain .10% of baseline, these changes were
defined as immune reactions. The reactions were clas-
sified into 3 subtypes, namely pre-, peri-, and posten-
graftment, according to the timing. Immune
reactions developing $6 days before engraftment
were defined as preengraftment immune reaction
(PIR), whereas reactions within 5 days of engraftment
were defined as engraftment syndrome (ES). Other
reactions were defined as postengraftment syndrome,
generally corresponding to aGVHD. Patients with
grade II-IV aGVHD were given 0.5-2.0 mg/kg/day
of prednisolone or methylprednisolone. Treatment
of immune reactions other than GVHD was at the
discretion of the physician.
Diagnostic Criteria for Early CNS Complication
Early CNS complications were defined as previ-
ously described [1]; those were defined as CNS toxicity
occurring within 100 days of transplantation. Diagno-sis of CNS complications was made by clinical, radio-
logic, or microbiologic findings (or a combination of
these). CNS complications that occurred after relapse
or progression of underlying diseases were excluded
from this analysis. The diagnosis of cyclosporine or
tacrolimus encephalopathy was based on the typical -
radiologic findings, that is, symmetrical white matter
lesions mainly localized in the occipital lobe. In
the case of limbic encephalopathy, the diagnosis was
based on selective involvement of the medial temporal
lobe on magnetic resonance imaging (MRI). A diagno-
sis of cerebrovascular diseases was confirmed by
neuroradiologic or postmortem studies (or both). Ab-
normalities on imaging were defined as areas of low
white-matter attenuation on computed tomographic
(CT) scans and as areas of T1-weighted hypointensity
and T2-weighted hyperintensity on magnetic reso-
nance imaging (MRI).Endpoints and Statistical Analysis
The endpoints of the present study were (1) to
investigate the incidence of early central nervous com-
plications after CBT for adults, and (2) to describe its
clinical characteristics.
A univariate Cox proportional hazards model was
used to assess the impact of potential risk factors for
the development of early CNS complication. All anal-
yses were conducted using the STATA version 9.2
software program (StataCorp, College Station, TX).RESULTS
Patient Characteristics and Transplantation
Outcomes
Characteristics of the 77 patients are shown in
Table 1. The preparative regimen includedmyeloabla-
tive CBT (n5 31) or RI-CBT (n5 46). Of 77 patients,
46 (60%) received fludarabine-based preparative regi-
mens, while 49 (64%) received TBI-containing pre-
parative regimens. GVHD prophylaxes were shown
in Table 1. The patients with methotrexate as
a GVHD prophylaxis are younger, received a cord
blood unit with higher HLA disparity, and more fre-
quently received a myeloablative preparative regimen
than those without methotrexate (data not shown).
All of the patients received a single cord blood unit.
The median age of the patients was 38 years (range:
18-64 years) for myeloablative CBT and 57 years
(range: 22-69 years) for RI-CBT.The primary diseases
included myeloid malignancy (n 5 43), lymphoid ma-
lignancy (n5 30), aplastic anemia (n5 3), and chronic
activated Epstein-Barr (EB)-virus infection (n 5 1).
The primary disease relapsed or progressed before pri-
mary neutrophil engraftment in 1 patient. Of the 76
patients, neutrophil engraftment was achieved in
Table 1. CBT Patient Characteristics
Variables Number
Age Median, range 48 (18-69)
Sex Male/female 31/46
Primary diseases Acute myeloid leukemia 30
Malignant lymphoma 11
Acute lymphoblastic leukemia 8
Chronic myelogenous leukemia 7
Adult T cell leukemia 7
Myelodysplastic syndrome 6
Aplastic anemia 3
Multiple myeloma 3
Chronic lymphocytic leukemia 1
Chronic activated EB-virus infection 1
Preparative regimens Myeloablative regimens
CY 120 mg/kg + TBI 8-12 Gy 9
BU 8 mg/kg + L-PAM 120-180 mg/m2 + TBI 10 Gy 7
L-PAM 180 mg/m2 + TBI 8-10 Gy 6
BU 8-16 mg/kg + CY 120 mg/kg + TBI 10 Gy 3
BU 16 mg/kg + CY 120 mg/kg 3
BU 8 mg/kg + CY 120 mg/kg + TBI 7.5 Gy 2
CA 2 g/m2 + CY 120 mg/kg + TBI 12 Gy 1
Reduced-intensity regimens
Flud 125-150 mg/m2 + L-PAM 80-140 mg/m2 + TBI 2-4 Gy 15
Flud 125 mg/m2 + L-PAM 60-180 mg/m2 + BU 4-8 mg/kg 11
Flud 125 mg/m2 + L-PAM 140-180 mg/m2 8
Flud 125-150 mg/m2 + CY 25-60 mg /kg + TBI 2-4 Gy 6
Flud 180 mg/kg + BU 8 mg/kg 3
Flud 125 mg/m2 + CY 30 mg/kg 1
Flud 180 mg/m2 + thio-tepa 10 mg/kg  2 + ATG 5 mg/kg 1
Flud 125 mg/m2 + VP-16 1800 mg/m2 + L-PAM 140 mg/m2 +
CY 120 mg/kg
1
Number of infused
nuclear cells
Median (range),  10E7/kg 2.50 (1.07-3.89)
Number of infused
CD34+ cells
Median (range),  10E6/kg 0.11 (0.02-8.65)
HLA matching 6/6 8
5/6 37
4/6 32
GVHD prophylaxis Cyclosporine alone 23
Tacrolimus alone 12
Cyclosporine + short-term MTX* 17
Tacrolimus + short-term MTX* 23
Cyclosporine + mPSL 1 mg/kg 2
Flud indicates fludarabine; CY, cyclophosphamide; BU, busulfan; L-PAM, melphalan; TBI, total body irradiation; CA, cytarabine; ATG, antithymocyte
globulin; GVHD, graft-versus-host disease; MTX, methotrexate; mPSL, methylprednisolone.
*MTXwas given at doses of 15 mg/m2, 10 mg/m2 and 10mg/m2 on days 1, 3, and 6 (n5 7), at doses of 10 mg/m2, 7 mg/m2 and 7 mg/m2 on days 1, 3, and 7
(n 5 15) and at doses of 6 mg/m2 and 4 mg/m2 on days 1 and 3 (n 5 1), respectively.
94 Biol Blood Marrow Transplant 15:92-100, 2009H. Narimatsu et al.54 patients. The median time to neutrophil engraft-
ment was 21 days (range: 10-69 days). Death occurred
before primary engraftment in 14 patients at a median
of day 18 (range: days 3-32). The overall survival (OS)
rate for the 77 patients was 52% (95% confidence
interval [CI], 40%-62%) at day 100. The OS rates
for the patients who underwent myeloablative CBT
and RI-CBT were 58% (95% CI, 39%-73%) and
48% (95% CI, 33%-61%) at day 100, respectively.
PIR developed in 28 patients, including the
patients with early CNS complications (n 5 7) and
the patients without such complications (n 5 21).
PIR was observed in 8 patients who had never been
engrafted. Of the 54 patients who underwent engraft-
ment, ES developed in 9 patients, including 1 patient
with early CNS complications (n5 1) and the patients
without such complications (n 5 8).Diagnosis of Early CNS Complications
Of the 77 patients, 10 (13%) developed early CNS
complications. The backgrounds of the 10 patients are
shown in Table 2. The causes included Cyclosporine
encephalopathy (n 5 4), tacrolimus encephalopathy
(n 5 2), transplantation-associated microangiopathy
(n 5 1), and unknown (n 5 3) (Table 3). No patients
developed early CNS complications due to medica-
tions other than calcineurin inhibitors. The basis for
diagnosis included an imaging study (n 5 3), labora-
tory findings (n 5 3), and clinical manifestation
(n 5 1) (Table 3).Clinical, Laboratory, and Radiologic Findings
The clinical and laboratory findings at the onset of
CNS complications are shown in Table 2. The median
Figure 1. T2-weighted magnetic resonance image of the brain showing
high-intensity signals in the occipital lobe. The patient was diagnosed to
have cyclosporine encephalopathy.
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tients developed impaired consciousness. Seizures de-
veloped in 6 patients. Four patients displayed fever at
the onset of CNS complications. Two patients demon-
strated a higher systolic blood pressure than 180
mmHg. Three patients displayed an elevated serum
creatinine level over 2.0 mg/dL. The serum sodium
and potassium levels ranged from 120 to 159 mEq
and from 2.9 to 5.1 mEq, respectively. Cerebrospinal
fluid obtained from 2 patients showed normal levels
of protein and cell counts. No pathogens such as bac-
teria or fungi, were cultured from the cerebrospinal
fluid.
Seven patients underwent an imaging study at on-
set of the CNS complications; CT in 4 and MRI in 6.
No patients displayed abnormal findings related to
CNS complications on CT. Four of the 6 patient dis-
played abnormalities in T2-weighted MRI; high-den-
sity signals in the cerebral cortex (n 5 1), temporal
lobes, frontal lobes, and thalamus (n 5 1), occipital
lobe (n 5 1) and hippocampus, and basal ganglia
(n 5 1) (Figure 1 and Table 3). No patients displayed
limbic encephalopathy.
Treatment and Outcome
The early CNS complications spontaneously sub-
sided in 3 patients. The complications responded to
cyclosporine or tacrolimus discontinuation in 3 pa-
tients. In the remaining 4 patients, the early CNS com-
plications seriously damaged their general conditions
and they died within 30 days of developing of early
CNS complications without improvement. The cause
of deaths included multiple organ failure (n 5 2),
hepatic failure (n 5 1). and primary disease (n 5 1).
Risk Factors
Risks factors for early CNS complications are
shown in Table 4. In the univariate analysis, no risk
factors for the onset of early CNS complications
were detected. An HLA disparity showed borderline
significance (hazard ratio, 3.24; 95% CI, 0.94-11.20;
P 5 .06).DISCUSSION
This is the first report of the incidence of early
CNS complications after CBT using myeloablative
and RI preparative regimens. The incidence of early
CNS complications was 13% in CBT. This is compa-
rable to or less than that in bone marrow transplanta-
tion (BMT) or peripheral blood stem cell
transplantation (PBSCT) [1,4,5,21-23], although the
information on the incidence of early CNS complica-
tions after allogeneic stem cell transplantation is lim-
ited. However, the early CNS complications after
CBT in adults suggest that poor outcomes will follow;namely, 40% of the patients with this complication
died without improvement within 30 days due to other
causes. Those indicated that early CNS complications
are a significant problem after CBT as well as in BMT
and PBSCT, and the clinician must be aware of the
possibility of these complications.
The present study revealed the calcineurin inhibi-
tors, such as cyclosporine and tacrolimus, are a major
cause of early CNS complication after CBT. Although
metabolic reasons have been reported to be a major
cause of encephalopathy in BMT or PBSCT, as well as
in our study [19,24], the incidence of encephalopathy
due to the calcineurin inhibitors in CBT was surpris-
ingly higher than that in BMT or PBSCT [5,19,22-
24]. One explanation for this higher incidence is that
the patientswho receivedCBTmore frequently develop
early immune reactions after CBT [15,19], which has
also been reported as ‘‘aGVHD before engraftment‘‘
or ‘‘hyperacute GVHD’’ [11,25], and therefore, physi-
cians might maximize the concentration of the calci-
neurin inhibitors, which might thus result in an
increase in the risk of early CNS complications. Al-
though it is difficult to evaluate the relationship between
the blood concentration andonset of earlyCNScompli-
cations in this study; no trends in the blood concentra-
tion were not observed in the patients with early CNS
complications (data not shown). However, our data in
the present study is limited and it is difficult to draw
adefinite conclusion.Thus, itmustbe investigated in fu-
ture studies. It isworth investigating the relationship be-
tween the areaunder the blood concentration timecurve
during the early posttransplantation period and the on-
set of early CNS complications. Another explanation is
Table 2. Characteristics of the Patients with Early CNS Complications
UPN Age Sex Primary Diseases
History of CNS
Complications
Infused Total
Cell Dose
(10E7) HLAmatch
Preparative
Regimen
GVHD
Prophylaxis
Medications before
Onset of CNS
Complications†
Neutrophil
Engraftment
(Day)
Post-CBT
Immune
Reaction
(Onset Day)
Treatment for
Post-CBT
Immune
Reaction
8 55 Male Adult T cell
leukemia/
lymphoma
No 2.76 4/6 Flud 125 mg/m2
+ L-PAM 180
mg + BU 8
mg/kg
Tac + MTX Teicoplanin,
micafungin,vancomycin,
cefepime, morphine
hydrochloride, heparin
23 No NA
9 30 Male Acute lymphoblastic
leukemia
No 1.71 5/6 BU 8 mg/kg +
L-PAM 120
mg/m2 +
TBI 10 Gy
Tac Amphotericin B,
piperacillin, cefepime,
intravenous
immunoglobulin,
heparin, morphine
hydrochloride
23 PIR (day14) PSL 2 mg/kg
13 27 Male Severe aplastic
anemia
No 3.1 4/6 CY 120 mg/kg
+ TBI 10 Gy
Tac + mPSL
1mg/kg
Aztreonam, amphotericin
B, albumin,
antithymocyte globulin,
teicoplanin,
tazobactam sodium/
piperacillin sodium,
heparin
Not engrafted No NA
21 60 Male Acute myeloid
leukemia
No 2.05 5/6 Flud 125 mg/m2
+ L-PAM 80
mg/m2 +
TBI 4 Gy
Csp Intravenous
immunoglobulin,
cefpirome, cefepime
23 PIR (day 5) mPSL 0.6 mg/kg
29 22 Female Chronic activate
EB-virus infection
No 3.05 4/6 Flud 125 mg/m2 +
L-PAM 140 +
TBI 2 Gy
Tac + MTX Micafungin, potassium
canrenoate, morphine
hydrochloride, fentanyl
citrate, intravenous
immunoglobulin,
biapenem, teicoplanin,
ceftazidime, cefepime,
ancomycin,
voriconazole
Not engrafted* No NA
33 46 Female NHL non-
Hodgkin’s
lymphoma
CNS involvement 3.06 5/6 L-PAM 180
mg/m2 +
TBI 10 Gy
Tac Cefepime, isepamicin,
imipenem, minocycline,
cefozopran
16 PIR (day3),
ES (day12)
Supportive care
41 52 Male Chronic
lymphocytic
leukemia
No 1.8 4/6 Flud 125 mg/m2+
L-PAM 80 mg/m2
+ TBI 4 Gy
Csp Allopurinol, cefepime,
isepamicin, furosemide,
meropenem,
micafungin, albumin
Not engrafted PIR (day 6) Supportive care
56 68 Female Myelodysplastic
syndrome/acute
myeloid leukemia
No 3.62 4/6 Flud 125 mg/m2
+ CY 30 mg/kg
+ TBI 4 Gy
Csp Polymixin B, furosemide,
metoclopramide,
hydroxyzine pamoate,
cefozopran
Not engrafted PIR (day13) Supportive care
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Biol Blood Marrow Transplant 15:92-100, 2009 97CNS Complications after CBTthat there are direct effects due to early immune reac-
tions. In recent basic studies, the vascular endothelial
cells could be activated by proinflammatory cytokines
that are secreted by T-lymphocytes and macrophages
early after hematopoietic cell transplantation, with the
ultimate consequence of a breakdown of vascular integ-
rity [26]. In the present study, 7 out of 10 patients dis-
played early immune reactions, such as preengraftment
immune reactions and engraftment syndrome, prior to
the development of CNS complications. Moreover,
HLA disparity marginally affected the onset of early
CNS complications, although it did not show statistical
significance. Mismatched antigens are a major target of
immune reactions including GVHD; thus, this result
supports this explanation. Multiple factors contribute
to the endothelial cell damage. In addition to early im-
mune reactions, direct toxicity of the conditioning regi-
men and calcineurin inhibitors, inflammatory cytokines
due to infections could involved in the development of
early CNS complications. Although fludarabine also
has a considerable degree of neurotoxicity [27,28], flu-
darabine-based RI preparative regimens were not re-
lated to the development of early CNS complications
(Table4),which is inconsistentwiththefindingsofapre-
vious study [1].This inconsistency indicates that the role
of fludarabine in early CNS complications thus remains
uncertain. Early CNS complications after CBT are in-
frequently accompanied by high blood pressure or elec-
trolyte disturbance, in contrast to those after BMT or
PBSCT.The clinical manifestations of early CNS com-
plications after CBTprobably differ to those after BMT
or PBSCT.
In the present study, the incidence of early CNS
complications in myeloablative CBT (13%) are almost
comparable to that in RI-CBT (15%), and no relation-
ship was detected between the preparative regimen and
the onset of early CNS complications. This indicated
that the preparative regimens had only a small impact
on the onset of early CNS complications; however, the
impact of total-body irradiation (TBI) must be dis-
cussed. Most of the RI preparative regimens included
low-doseTBI in the present study.TBI is thought to in-
jure the blood-brain barrier, and subsequently increase
the risk of cyclosporine/tacrolimus encephalopathy.
Therefore, an RI preparative regimen might not have
decreased the incidence of early CNS complications.
The present study demonstrated the clinical char-
acteristics of early CNS complications after CBT, al-
though some issues remain to be discussed. First, this
is a small retrospective study so an unrecognized bias
might have affected the result. The rate of engraftment
was low both among the patients with early CNS com-
plications and the patients without such complications.
This also might have affected the results. Second, the
patients in the present study were diagnosed based
on clinical findings without a pathologic examination.
Therefore, the incidence of early CNS complications
Table 3. Clinical,Llaboratory, and Radiologic Characteristics at the Onset of CNS complications
Clinical Findings Laboratory Findings Radiologic Examination
UPN Cause
CNS
Complication
Onset Day
Chief Basis
for Diagnosis
Impaired
Consciousness Seizures
Fiver
$38C
Systolic
Blood
Pressure
(mmHg)
Diastolic
Blood
Pressure
(mmHg)
Cyclosporine/
tacrolimus
(ng/mL)
Mg
(mEq)
Cerebrospinal
fluid((number of
multinuclear cell/
mononuclear
cell)/mL)
CT/T2-
Weighted MRI
Treatment
to CNS
Complication
Outcome of
the CNS
Complication
Outcome of the
Transplantation
8 Tacrolimus
encephalopathy
27 High concentration
of tacrolimus
Yes No No 140 70 15.28 (steady-
state level)
1.6 ND ND/ND Observation Improved Died due to primary
disease at day 348
9 Unknown 2 NA Yes Yes Yes 190 110 ND 2.5 ND ND/Normal Observation Improved Died due to intestinal
hemorrhage at day 32
13 Tacrolimus
encephalopathy
58 MRI Yes Yes No 130 62 3.3 (steady-
state level)
1.6 ND ND/diffuse high-
density signals in
cerebral cortex
Observation Improved Died due to pneumonia
at day 244
21 Cyclosporine
encephalopathy
22 Therapeutic
diagnosis
Yes No No 148 88 161 (trough
level)
ND ND ND/ND Discontinuation
of cyclosporine
Improved Died due to
encephalopathyat
day 36
29 Transplantation-
associated
microangiopathy
19 Thrombocytopenia
with hemolytic
anemia and
renal dysfunction
Yes No No 119 64 #0.5 (steady-
state level)
2.3 ND Normal/ND Hemodialysis Died due
to multiple-organ
failure at day 21
without
improvement
—
33 Unknown 17 NA Yes Yes Yes 133 64 11.2 (steady-
state level)
ND 0/2 Ischemic change in
cerebral white
matter/high-density
signals in temporal
lobes, frontal lobes
and thalamus
Discontinuation
of tacrolimus,
acyclovir
Improved Disease relapsed at
day 114 and
died at 158
41 Cyclosporine
encephalopathy
11 High concentration
of cyclosporine
with renal
disfunction
Yes No Yes 106 58 378 (steady-
state level)
ND ND ND/ND Discontinuation
of cyclosporine,
hemodialysis
Died due to
hepatic failure
at day 23
without
improvement
—
56 Cyclosporine
encephalopathy
19 MRI Yes Yes No 193 107 138 (trough
level)
ND 0/0 Normal/High-
density signals
in occipital lobe
Discontinuation
of cyclosporine
Improved Died due to invasive
aspergillosis at
day 52
61 Cyclosporine
encephalopathy
16 MRI Yes Yes No 130 90 145 (trough
level)
1.9 ND ND/high-density
signals in hippocampus
and basal ganglia
Discontinuation
of cyclosporine
Died due to
multiple-organ
failure at day
45 without
improvement
—
64 Unknown 23 NA Yes Yes Yes 128 90 263 (trough
level)
ND ND Normal/normal Observation Disease relapsed
at day 34 and
the patient
died at day 52
without
improvement
—
NA indicates not applicable; ND, not done; MRI, magnetic resonance imaging; CNS, central nervous system.
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Table 4. Risk Factors for Onset of Early CNS Complications
Univariate Factors HR 95%CI P
Age (linear by 1-year increase) 1.00 0.96 -1.05 .81
Sex (male vs. female) 0.97 0.27 -3.43 .96
Risk of underlying
disease (high vs. low)
0.81 0.23 -2.87 .74
Previous transplant 1.04 0.22 -4.91 .96
Blood type mismatch 0.39 0.11 -1.41 .15
Infused total
nuclear cell (linear by 110E7 increase)
2.78 0.81 -9.62 .11
HLA disparity (linear by 1/6 increase) 3.24 0.94 -11.20 .06
Preparative regimen
Total body irradiation 5.67 0.72 -44.81 0.10
Myeloablative vs reduced-intensity regimen 1.60 0.41 -6.19 0.50
HR indicates hazard ratio; CI, confidence interval; CNS, cnetral nervous
system.
Biol Blood Marrow Transplant 15:92-100, 2009 99CNS Complications after CBTmight be overestimated. Third, human herpes virus-6
(HHV-6) encephalitis has been reported in CBT
as well as in T cell-depleted allogeneic stem cell
transplantation [29,30]. Because cord blood does not
contain antigen-exposed cells during early-phase im-
mune recovery with peripheral expansion of mature
T cells transferred with the graft, immune reconstitu-
tion is slow, and this leads to an increased risk of
complications by viruses. In the present study, no viro-
logic study of cerebrospinal fluid was conducted in the
patientswith earlyCNScomplications. BecauseHHV-
6 encephalopathy usually displays limbic encephalopa-
thy on imaging studies [31], the diagnosis is unlikely in
those 6 patients who received T2-weightedMRI in the
present study. However, this possibility cannot be
completely eliminated in the remaining 4 patients. En-
cephalopathy by viruses in CBT has to be investigated
in future studies. Finally, the risk factors for early CNS
complications in CBT have to be identified in larger
seized studies, because the present study did not have
sufficient statistical power due to the small sample
size. In particular, posttransplant events, such as preen-
graftment immune reaction, engraftment syndrome,
and additional steroid use for those immune reactions,
therefore need to be investigated in future studies to
establish an optimal management protocol.ACKNOWLEDGMENTS
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chi (National Hospital Organization Nagoya Medical
Center, Clinical Research Center, Nagoya), Masato
Watanabe (Fujita Health University Hospital,
Toyoake), Akio Kohno (JA Aichi Konan Kosei Hospi-
tal, Konan), Hiroto Narimatsu, Makoto Murata (Na-
goya University Hospital, Nagoya), and Masashi
Sawa (Anjo Kosei Hospital, Anjo, Japan).REFERENCES
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